Navidea Biopharmaceuticals to Present at the Needham 12th Annual Healthcare
– Chief Executive Officer to Provide Business and Development Program Updates
Needham Healthcare Conference 2013
DUBLIN, Ohio -- April 25, 2013
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company
focused on precision diagnostic radiopharmaceuticals, today announced that Dr.
Mark Pykett, President and Chief Executive Officer, will participate at the
Needham 12^th Annual Healthcare Conference on April 30 - May 1, 2013 at the
Westin Grand Central Hotel, New York City. Dr. Pykett will provide an update
of the Company and its development programs on Wednesday, May 1, 2013 at 3:40
Investors and the public are invited to listen to a live webcast of Dr.
Pykett’s presentation at http://wsw.com/webcast/needham58/navb/. Following the
conference, the webcast will be archived for approximately 30 days.
About Navidea Biopharmaceuticals Inc.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical
company focused on the development and commercialization of precision
diagnostics and radiopharmaceutical agents. Navidea is actively developing
four radiopharmaceutical agent platforms – Lymphoseek^®, NAV4694, NAV5001 and
RIGScan^TM – to help identify the sites and pathways of undetected disease and
enable better diagnostic accuracy, clinical decision-making and, ultimately,
patient care. Navidea’s strategy is to deliver superior growth and shareholder
return by bringing to market novel radiopharmaceutical agents and advancing
the Company’s pipeline through selective acquisitions, global partnering and
commercialization efforts. For more information, please visit www.navidea.com.
Brent Larson, Sr. VP & CFO
Press spacebar to pause and continue. Press esc to stop.